6. de Feyter PJ. Percutaneous treatment of saphenous vein bypass graft obstructions: a continuing obstinate problem. 7. Bejarano J. Mechanical protection of cardiac microcirculation during percuta-neous coronary interevntion of saphenous vein grafts. Int J Cardiol. In press. 8. Baim DS, Wahr D, George B, et al. Randomized trial of a distal embolic protection device during percutaneous intervent...

Percutaneous coronary intervention in the setting of coronary bifurcation lesions is associated with increased risk for complications. The goal of this manuscript is to review the currently available classifications for coronary artery bifurcation lesions with a guide to the use of specific coronary bifurcation techniques based on lesion characteristics

coronary artery perforation is a rare, but potentially serious, complication of percutaneous coronary intervention and is associated with a high incidence of death, q-wave myocardial infarction, and emergency coronary bypass surgery. management is different but requires prompt recognition and treatment. we describe a case of coronary perforation only after guidewire removal and also review the ...

Background—Factor Xa and factor IIa (thrombin) play roles in thrombotic complications after percutaneous coronary intervention. M118 is a novel low–molecular-weight heparin that has been rationally designed to capture the desired attributes of unfractionated heparin (UFH) and low–molecular-weight heparin: Potent activity against factor Xa and IIa, predictable pharmacokinetics after both intrave...

INTRODUCTION Glycoprotein IIb/IIIa inhibitors are recommended by guidelines in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. There are few studies directly comparing these agents. The aim of this study was to assess whether eptifibatide is a safe and cost-effective alternative to abciximab in the treatment of primary percutaneo...

BACKGROUND Factor Xa and factor IIa (thrombin) play roles in thrombotic complications after percutaneous coronary intervention. M118 is a novel low-molecular-weight heparin that has been rationally designed to capture the desired attributes of unfractionated heparin (UFH) and low-molecular-weight heparin: Potent activity against factor Xa and IIa, predictable pharmacokinetics after both intrave...

Background The local injection of novel cardioprotective study drugs prior to percutaneous coronary intervention could cause embolisation of thrombus, resulting in increased reperfusion injury and subsequent infarct size. The aim of this study was to assess the safety of the delivery of an intracoronary therapy delivered during primary percutaneous coronary intervention for acute myocardial inf...

AIMS Although hirudin is superior to unfractionated heparin for prevention of death, myocardial infarction, or refractory ischaemia in patients with non-ST-elevation acute coronary syndrome, it is not clear whether hirudin is also of benefit in acute coronary syndrome patients undergoing early percutaneous coronary intervention. METHODS AND RESULTS In the OASIS 2 trial, 10 141 patients with n...

BACKGROUND Registry studies have suggested improvements in door-to-balloon times, but a national assessment of the trends in door-to-balloon times is lacking. Moreover, we do not know whether improvements in door-to-balloon times were shared equally among patient and hospital groups. METHODS AND RESULTS This analysis includes all patients reported by hospitals to the Centers for Medicare & Me...

Perioperative myocardial ischemia is rare but serious complication of CABG. Graft dysfunction, coronary artery thrombosis and incomplete revascularization are main causes. Pharmacological treatment, intra aortic counter pulsation and immediate additional grafting have limited results. Treatment strategy based on coronary angiography findings could lessen the burden of high mortality rate in the...